Finance

Lists
TRUMY:OTCMKTS
Terumo ADR
USD 14,64
+0,90%
(+0,13) 1D
16 Okt., 15:33:32 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRUMY...
Open
USD 14,57
High
USD 14,74
Low
USD 14,57
Mkt. cap
3,46 bn
Avg. vol.
115,96 k
Volume
72,57 k
52-wk high
USD 17,81
52-wk low
USD 12,08
Beta
0,77
Shares outstanding
1,48 mjd
No. of employees
31 k
Open
USD 14,57
High
USD 14,74
Low
USD 14,57
Mkt. cap
3,46 bn
Avg. vol.
115,96 k
Volume
72,57 k
52-wk high
USD 17,81
52-wk low
USD 12,08
Beta
0,77
Shares outstanding
1,48 mjd
No. of employees
31 k
News stories
From web sources and news partners
Profile
Terumo Corporation was founded in 1921 as Red Line Thermometer Corporation by a group of medical scientists led by Dr. Kitasato Shibasaburō to produce medical thermometers in Japan. The company's first product was "Jintan Taionkei", the first Japanese-made thermometer available for sale, and it has since expanded into a medical devices manufacturer, producing medical disposables, cardiovascular systems and diabetes care products. In 1971, Terumo opened its first overseas office in the United States. Since then, the company has established subsidiaries in Europe, South America, China, India, Philippines, Vietnam, Thailand, Australia and México. The company later expanded its product range to include coronary stents and catheters, and acquired, among others, the cardiovascular specialty companies Vascutek and Microvention in 2002 and 2006 respectively. Wikipedia
About Terumo ADR
CEO-
Employees31,2 k
Founded17 Sep. 1921
HeadquartersShibuya, Tokio, Japan
SectorMedical device
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
274,96 mjd
296,63 mjd
300,32 mjd
311,81 mjd
Cost of goods sold
127,97 mjd
143,44 mjd
149,06 mjd
133,27 mjd
Cost of revenue
127,97 mjd
143,44 mjd
149,06 mjd
133,27 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
97,88 mjd
105,26 mjd
107,66 mjd
109,70 mjd
Operating expense
101,90 mjd
109,31 mjd
98,62 mjd
89,06 mjd
Total operating expenses
229,87 mjd
252,74 mjd
247,68 mjd
222,33 mjd
Operating income
45,10 mjd
43,88 mjd
52,64 mjd
89,48 mjd
Other non operating income
-1,00 m
2,00 m
-409,00 m
-4,00 m
EBT including unusual items
45,95 mjd
45,38 mjd
31,66 mjd
90,32 mjd
EBT excluding unusual items
45,95 mjd
45,38 mjd
52,86 mjd
90,32 mjd
Income tax expense
10,90 mjd
12,72 mjd
5,30 mjd
19,89 mjd
Effective tax rate
23,72%
28,04%
16,73%
22,03%
Other operating expenses
4,02 mjd
4,05 mjd
-9,05 mjd
-20,64 mjd
Net income
35,05 mjd
32,65 mjd
26,37 mjd
70,43 mjd
Net profit margin
12,75%
11,01%
8,78%
22,59%
Earnings per share
-
-
-
-
Interest and investment income
1,02 mjd
2,21 mjd
-
2,38 mjd
Interest expense
-18,00 m
-463,00 m
-1,32 mjd
-1,48 mjd
Net interest expenses
1,00 mjd
1,75 mjd
-1,32 mjd
905,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
66,76 mjd
69,98 mjd
79,07 mjd
116,67 mjd
Gain or loss from assets sale
4,72 mjd
154,00 m
188,00 m
12,00 m
AI content may include mistakes. Learn more
Google-programme